Investors reposed faith in our future growth prospects: Syngene

Last Updated: Thursday, July 30, 2015, 16:51

Readying to list its shares after a bumper 32-times over-subscribed IPO, biotechnology major Biocon's research arm Syngene on Thursday said the investors have reposed faith in its future growth prospects.

SEBI's insider trading norms 'draconian': Biocon's Shaw

Last Updated: Friday, July 24, 2015, 22:47

In a sharp criticism of regulator SEBI's new insider trading norms, industry leader and Biocon chief Kiran Mazumdar Shaw Friday said these rules have "draconian intent" and will kill the ESOPs.

Biocon sets price band at Rs 240-250 for research arm's IPO

Last Updated: Thursday, July 16, 2015, 09:10

Biotechnology major Biocon Ltd has set the price band at Rs 240-250 per equity share for the initial public offering of its research arm Syngene International Ltd.

Syngene gets nod to raise foreign investment to 44%

Last Updated: Monday, June 22, 2015, 15:27

Syngene, a subsidiary of Biocon, on Monday said it has received the Foreign Investment Promotion Board (FIPB) approval for raising foreign investment in the company to 44 percent from the earlier approved 10 percent.

Govt approves FDI worth Rs 4,000 cr in pharma sector

Last Updated: Wednesday, June 17, 2015, 17:15

Proposals for foreign direct investment amounting to around Rs 4,000 crore by four pharma and medical devices firms, including Torrent Pharmaceuticals and Biocon's research services arm Syngene, were on Wednesday approved by the government.

Biocon shares end higher as arm Syngene gets Sebi nod for IPO

Last Updated: Tuesday, June 16, 2015, 18:37

After surging 2.93 percent to Rs 460 in intraday trade, shares of Biocon ended at Rs 453.75, up 1.53 percent on the BSE.

Biocon shares gain 3% as arm Syngene gets Sebi nod for IPO

Last Updated: Tuesday, June 16, 2015, 12:41

As per the draft papers, the company plans to sell 22 million equity shares, including reservation of up to two million shares for Biocon shareholders, through an offer for sale. Of the total shares on offer, 50 percent has been reserved for qualified institutional buyers, 15 percent for high net worth individuals and the rest for retail investors.

Biocon's arm Syngene gets SEBI nod for IPO

Last Updated: Monday, June 15, 2015, 20:15

Syngene International, research arm of biotechnology major Biocon, has received capital markets regulator SEBI's approval to launch an initial public offer (IPO).

Biocon, Mylan drug discovery programme makes progress

Last Updated: Thursday, May 7, 2015, 14:01

Biocon shares were trading at Rs 425.90 apiece, up 0.16%, on the BSE.

Biocon Q4 consolidated net surges 78%

Last Updated: Thursday, April 30, 2015, 11:31

During the quarter, Biocon reported exceptional gain of Rs 105.06 crore on account of share sale in its research services subsidiary Syngene.

Biocon files IPO prospectus for R&D arm Syngene

Last Updated: Thursday, April 23, 2015, 10:07

Biotech firm Biocon Ltd has filed a prospectus for the initial public offering of its USD 600 million research and development arm, Syngene, it said on Thursday.

Biocon files prospectus for Syngene IPO to raise Rs 600 cr

Last Updated: Wednesday, April 22, 2015, 20:00

Biotechnology major Biocon Wednesday filed prospectus with market regulator SEBI for the initial public offer of its research arm Syngene through which aims to raise around Rs 600 crore that will be used to fund its R&D programmes.